News >

High Response Rate in Histiocytic Disease With MEK Inhibition

Gina Columbus @ginacolumbusonc
Published: Wednesday, Jan 03, 2018

Five patients remained on the 60-mg starting dose of cobimetinib. The dosage was reduced to 40 mg for 8 patients, and 2 patients had a reduced dosage to 20 mg.

“The safety and tolerability have been similar to other studies of cobimetinib,” Diamond said. “One patient was removed for toxicity, but none for intolerable side effects. The optimal duration and dosing of cobimetinib remain unknown.”
Diamond EL, Durham BH, Dogan A, et al. Phase 2 trial of single-agent cobimetinib for adults with BRAF V600-mutant and wild-type histiocytic disorders. In: Proceedings from the 59th ASH Annual Meeting and Exposition; December 9-12, 2017; Atlanta, GA. Abstract 257.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x